Epratuzumab

From Self-sufficiency
Jump to: navigation, search
Epratuzumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CD22
Identifiers
CAS Number 205923-57-5
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).[1][2] The manufacturers in August 2009 announced success in early trials against SLE.[3]

Mechanism

Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells, which it destroys by antibody-dependent cell-mediated cytotoxicity.[4]

See also

External links

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1, 2003 free full text
  2. Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research Vol. 11, July 15, 2005 free full text
  3. Reuters: UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)
  4. National Cancer Institute: Epratuzumab